New stock news: Apsaras Bio submits application to Hong Kong Stock Exchange to improve current limited efficacy of cancer treatment options.

Wisdom Financial APP learned that, according to the disclosure of the Hong Kong Stock Exchange on August 25, InxMed Limited has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citic Securities and China Construction Bank International as its joint sponsors. According to the prospectus, InxMed Limited is a biotechnology company founded in 2017 that is in the late clinical stage, dedicated to improving current limited efficacy in cancer treatment. The company's mission is to address the core challenge of cancer treatment - drug resistance caused by tumor defense.